Nome |
# |
Primary mediastinal large B-cell lymphoma, file e3835318-be68-15e8-e053-a505fe0a3de9
|
1.427
|
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi, file e3835318-d366-15e8-e053-a505fe0a3de9
|
1.037
|
Primary mediastinal lymphoma: diagnosis and treatment options., file e3835318-afde-15e8-e053-a505fe0a3de9
|
656
|
Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?, file e3835318-d6c1-15e8-e053-a505fe0a3de9
|
499
|
Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL), file e3835318-855b-15e8-e053-a505fe0a3de9
|
483
|
The 68Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma), file e3835318-7e23-15e8-e053-a505fe0a3de9
|
281
|
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper, file e3835318-c565-15e8-e053-a505fe0a3de9
|
243
|
Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume., file e3835321-bf6f-15e8-e053-a505fe0a3de9
|
234
|
Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply, file e3835318-0261-15e8-e053-a505fe0a3de9
|
151
|
Diffuse large B-cell lymphoma., file e3835312-3fb6-15e8-e053-a505fe0a3de9
|
147
|
Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, file e3835318-bdca-15e8-e053-a505fe0a3de9
|
136
|
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma, file e3835318-7c7d-15e8-e053-a505fe0a3de9
|
131
|
null, file e383532a-72ca-15e8-e053-a505fe0a3de9
|
124
|
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy, file e3835327-0791-15e8-e053-a505fe0a3de9
|
94
|
COVID-19 in patients with hematologic disorders undergoing therapy: perspective of a large referral hematology center in Rome, file e3835328-7592-15e8-e053-a505fe0a3de9
|
87
|
In Reply to Adams and Kwee, file e3835318-7e1d-15e8-e053-a505fe0a3de9
|
86
|
Cytological diagnostic features of late breast implant seromas. From reactive to anaplastic large cell lymphoma, file e3835317-dbb0-15e8-e053-a505fe0a3de9
|
83
|
Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study, file e3835326-e5d3-15e8-e053-a505fe0a3de9
|
70
|
Reduced transmission of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) in patients with haematological malignancies hospitalized in an Italian hospital during the COVID-19 pandemic, file e383532d-934c-15e8-e053-a505fe0a3de9
|
65
|
Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL, file 999a445c-5881-4183-af06-009237019020
|
36
|
High basal maximal standardized uptake value (Suvmax) in follicular lymphoma identifies patients with a low risk of long-term relapse, file e383532c-a95a-15e8-e053-a505fe0a3de9
|
21
|
Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study., file e3835312-3fb7-15e8-e053-a505fe0a3de9
|
18
|
Lymphadenopathies before and during the pandemic COVID-19: increasing incidence of metastases from solid tumors, file a22197bc-b205-4ebc-8c46-c227aa3317b0
|
16
|
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma, file e3835318-a6bb-15e8-e053-a505fe0a3de9
|
14
|
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report, file 61281648-2c18-473a-aa8a-2e40962c9780
|
13
|
Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL), file e383532f-1b71-15e8-e053-a505fe0a3de9
|
13
|
Long-term host immune modulation following tisagenlecleucel administration in patients with diffuse large b-cell lymphoma and b-lineage acute lymphoblastic leukemia, file 64433d44-d310-48ee-b694-799f96d423a3
|
12
|
Whole body MRI with diffusion weighted imaging versus 18F‑fuorodeoxyglucose‑PET/CT in the staging of lymphomas, file 6e924d4e-3c5d-4a71-b08a-990fabc419df
|
12
|
Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature review, file e3835311-ae9b-15e8-e053-a505fe0a3de9
|
10
|
Bing-Neel syndrome coexisting with oligodendroglioma, file e383532f-04ce-15e8-e053-a505fe0a3de9
|
8
|
Surgery in primary gastric lymphoma: impact on clinical staging and long-term survival., file e3835311-e0e1-15e8-e053-a505fe0a3de9
|
7
|
Relapsed/Refractory Multiple Myeloma Patients. A Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy, file e383532e-36ae-15e8-e053-a505fe0a3de9
|
7
|
Efficacy of residual site radiation therapy (ISRT) in patients with primary mediastinal lymphoma with Deauville Score 4 following R-CHT: results of a retrospective mono institutional study, file 3f92368c-fa7a-4dbd-b0b8-5e288d43c1b7
|
5
|
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy, file e3835328-bff2-15e8-e053-a505fe0a3de9
|
5
|
Corrigendum to "Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept: A case report and literature review" [Leuk. Res. 36 (2012) e199-e201], file e3835318-ad25-15e8-e053-a505fe0a3de9
|
4
|
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy. results from a monoinstitutional cohort analysis of long-term survivors, file e3835317-94bc-15e8-e053-a505fe0a3de9
|
3
|
null, file e3835328-d391-15e8-e053-a505fe0a3de9
|
3
|
Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients, file e383532b-d561-15e8-e053-a505fe0a3de9
|
3
|
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib, file e383532c-6218-15e8-e053-a505fe0a3de9
|
3
|
Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome, file e383532d-0575-15e8-e053-a505fe0a3de9
|
3
|
Reduced Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) colonization in a hematological-emergency setting during the coronavirus disease 2019 (COVID-19) pandemic, file 5dd99ce4-b9f4-4cb4-bf83-8cd5517f1ee6
|
2
|
Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience, file 77fdd332-1ffa-451a-944d-03f9040c0ab0
|
2
|
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): Final results of a multicentre, open-label, randomised, controlled, phase 3 study, file e3835318-7820-15e8-e053-a505fe0a3de9
|
2
|
Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy, file e3835318-c980-15e8-e053-a505fe0a3de9
|
2
|
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma, file e383531a-d495-15e8-e053-a505fe0a3de9
|
2
|
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death, file e3835321-9f42-15e8-e053-a505fe0a3de9
|
2
|
Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study, file 0176a3de-e0f5-4d6a-b5db-1a35177cf1bc
|
1
|
Neoplastic bone marrow invasion:rapid exclusion of hematological disease by flow cytometric routine panels, file 40ffc73c-69de-40a7-ae83-b6228b8dd3aa
|
1
|
Case Report: Infectious prophylaxis in hematological malignancies, file 5421b9b3-d1ac-442f-8877-a46caefa38e2
|
1
|
Editorial: HBV and lymphoma, file 6ae3d2fc-d20c-4087-bf2b-a2ebcf26b180
|
1
|
Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study, file 875a0f21-092e-4a8f-843a-6bf670251e4c
|
1
|
Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study, file b1d8a0cd-7428-4238-a778-a64aa7a69f4b
|
1
|
Effectiveness of Fludarabine, Idarubicin and Cyclophosphamide (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin's Lymphoma., file e3835311-8e83-15e8-e053-a505fe0a3de9
|
1
|
Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): Results of prospective study with multimodality therapeutic approach, file e3835311-9c40-15e8-e053-a505fe0a3de9
|
1
|
[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study., file e3835312-6bcd-15e8-e053-a505fe0a3de9
|
1
|
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma, file e3835318-05b6-15e8-e053-a505fe0a3de9
|
1
|
A MALT lymphoma prognostic index, file e3835318-1a16-15e8-e053-a505fe0a3de9
|
1
|
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma, file e3835318-75a3-15e8-e053-a505fe0a3de9
|
1
|
Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study, file e3835318-7745-15e8-e053-a505fe0a3de9
|
1
|
Nodal aggressive non Hodgkin’s lymphoma in the adult., file e3835318-788c-15e8-e053-a505fe0a3de9
|
1
|
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41), file e3835318-7a49-15e8-e053-a505fe0a3de9
|
1
|
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma, file e3835318-7e1f-15e8-e053-a505fe0a3de9
|
1
|
How to identify patients at risk of developing lymphomatous meningitis [Come identificare i pazienti a rischio di sviluppare meningite linfomatosa], file e3835318-8185-15e8-e053-a505fe0a3de9
|
1
|
Lung cancer after treatment for non-Hodgkin lymphoma., file e3835318-83e9-15e8-e053-a505fe0a3de9
|
1
|
Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: Interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study, file e3835318-b3dd-15e8-e053-a505fe0a3de9
|
1
|
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL., file e3835321-bb95-15e8-e053-a505fe0a3de9
|
1
|
Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma, file e3835323-0a00-15e8-e053-a505fe0a3de9
|
1
|
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma, file e3835328-4e6d-15e8-e053-a505fe0a3de9
|
1
|
Totale |
6.284 |